Literature DB >> 28815631

Comparison and interpretability of the available urticaria activity scores.

T Hawro1, T Ohanyan1, N Schoepke1, M Metz1, A Peveling-Oberhag2, P Staubach2, M Maurer1, K Weller1.   

Abstract

The urticaria activity score (UAS) is the gold standard for assessing disease activity in patients with chronic spontaneous urticaria (CSU). Two different versions, the UAS7 and UAS7TD , are currently used in clinical trials and routine care. To compare both versions and to obtain data on their interpretability, 130 CSU patients applied both versions and globally rated their disease activity as none, mild, moderate, or severe. UAS7 and UAS7TD values correlated strongly (r = .90, P < .001). Interquartile ranges for UAS7 and UAS7TD values for mild, moderate, and severe CSU were 11-20 and 10-24, 16-30 and 16-32, and 27-37 and 28-40. UAS7 values were slightly, but significantly lower as compared to UAS7TD values (mean difference: 1.6 ± 4.6, P < .001). This difference was driven by lower wheal subscores (2.1 ± 3.5, P < .001) and was most pronounced in patients with severe CSU (2.5 ± 5.6, P < .01). The UAS7/UAS7TD ratio was 0.96 ± 0.21 and did not differ significantly between mild, moderate, and severe CSU. Since the results of both UAS versions are comparable, we recommend the use of the UAS7, which is less burdensome in administration and scoring.
© 2017 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Entities:  

Keywords:  disease activity; patient-reported outcomes; pruritus; urticaria; urticaria activity score

Mesh:

Substances:

Year:  2017        PMID: 28815631     DOI: 10.1111/all.13271

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  11 in total

Review 1.  Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients With Chronic Idiopathic (Spontaneous) Urticaria: A Meta-analysis of "Real-world" Evidence.

Authors:  Michael D Tharp; Jonathan A Bernstein; Abhishek Kavati; Benjamin Ortiz; Karen MacDonald; Kris Denhaerynck; Ivo Abraham; Christopher S Lee
Journal:  JAMA Dermatol       Date:  2019-01-01       Impact factor: 10.282

2.  Advances in drug allergy, urticaria, angioedema, and anaphylaxis in 2018.

Authors:  Rachel L Miller; Maria Shtessel; Lacey B Robinson; Aleena Banerji
Journal:  J Allergy Clin Immunol       Date:  2019-06-24       Impact factor: 10.793

Review 3.  Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020.

Authors:  Marcus Maurer; Kilian Eyerich; Stefanie Eyerich; Marta Ferrer; Jan Gutermuth; Karin Hartmann; Thilo Jakob; Alexander Kapp; Pavel Kolkhir; Désirée Larenas-Linnemann; Hae-Sim Park; Gunnar Pejler; Mario Sánchez-Borges; Knut Schäkel; Dagmar Simon; Hans-Uwe Simon; Karsten Weller; Torsten Zuberbier; Martin Metz
Journal:  Int Arch Allergy Immunol       Date:  2020-03-30       Impact factor: 2.749

4.  Sleep Disturbance in Patients with Urticaria and Atopic Dermatitis: An Underestimated Burden.

Authors:  Caroline Mann; Matthias Dreher; Hans-Günter Weeß; Petra Staubach
Journal:  Acta Derm Venereol       Date:  2020-03-12       Impact factor: 3.875

5.  Impact of Chronic Urticaria on the Self-Assessed Health Status.

Authors:  Jae Hyun Lee
Journal:  Allergy Asthma Immunol Res       Date:  2020-07       Impact factor: 5.764

6.  Adaptation and Validation of the Korean Version of the Urticaria Control Test and Its Correlation With Salivary Cortisone.

Authors:  Ji Ho Lee; Yoon Ju Bae; So Hee Lee; Su Chin Kim; Hyun Young Lee; Ga Young Ban; Yoo Seob Shin; Hae Sim Park; Juergen Kratzsch; Young Min Ye
Journal:  Allergy Asthma Immunol Res       Date:  2019-01       Impact factor: 5.764

7.  Validation of the Turkish version of the Urticaria Control Test: Correlation with other tools and comparison between spontaneous and inducible chronic urticaria.

Authors:  Emek Kocatürk; Utkan Kızıltaç; Pelin Can; Rabia Öztaş Kara; Teoman Erdem; Kübra Kızıltaç; Nagihan Sahillioğlu; Aslı Gelincik; Marcus Maurer; Karsten Weller
Journal:  World Allergy Organ J       Date:  2019-01-26       Impact factor: 4.084

8.  Socio-economic burden and resource utilisation in Italian patients with chronic urticaria: 2-year data from the AWARE study.

Authors:  Oliviero Rossi; Angelo Piccirillo; Enrico Iemoli; Annalisa Patrizi; Luca Stingeni; Stefano Calvieri; Massimo Gola; Paolo Dapavo; Antonio Cristaudo; Leonardo Zichichi; Laura Losappio; Fabiana Saccheri; Elide Anna Pastorello
Journal:  World Allergy Organ J       Date:  2020-12-08       Impact factor: 4.084

9.  Chronic spontaneous urticaria activity, impact and control as well as their changes are strongly linked, and these links are not affected by angioedema or comorbid inducible urticaria - Results from the validation of the Polish Urticaria Control Test.

Authors:  Zenon Brzoza; Karina Badura-Brzoza; Marcus Maurer; Tomasz Hawro; Karsten Weller
Journal:  World Allergy Organ J       Date:  2022-03-21       Impact factor: 4.084

10.  Efficacy of acupuncture treatment for chronic spontaneous urticaria: study protocol for a randomised controlled trial.

Authors:  Qianhua Zheng; Hui Zheng; Siyuan Zhou; Yunzhou Shi; Leixiao Zhang; Xianjun Xiao; Wei Zhang; Li Zhou; Ying Huang; Mingling Chen; Feng Zhong; Chuan Wang; Ying Li
Journal:  BMJ Open       Date:  2022-02-01       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.